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student from Olmsted Falls, Ohio; Andrew Roecker, PharmD '00, BCPS, associate professor of pharmacy practice; 
Tarek Mahfouz, Ph.D., assistant professor of pharmaceutical chemistry 
This knowledge-based activity is targeted for all pharmacists and is 
acceptable for 1.0 hour (0.1 CEU) of continuing education credit. This 
course requires completion of the program evaluation and at least a 
I 70 percent grade on the program assessment questions. 
ACPE Universal Activity Number (UAN): 0048-0000-11-026-H01-P 
Objectives: 
After completion of this program, the reader should be able to: 
1. Define the types of MRSA 
2. List the medications that can be used to treat CA-MRSA 
3. List the medications that can be used to treat HA-MRSA 
4. Identify how MRSA can be transmitted in the community and health 
care settings 
5. Distinguish the importance of evidence-based medicine and pub-
lished guidelines in helping with antibacterial resistance 
6. State the preferred treatments of MRSA in certain clinical syndromes 
Abstract 
As of February 2011, the Infectious Disease Society of America 
(IDSA) published the first guidelines assessing the treatment of 
methicillin-resistant Staphylococcus aureus (MRSA} infections. S. 
aureus is present in the environment and is also located on the 
skin's surface. MRSA can cause a variety of clinical syndromes pre-
senting with different symptoms that vary with the type and stage 
of the infection. MRSA is also classified into community-acquired 
MRSA (CA-MRSA) and hospital-acquired MRSA (HA-MRSA), both 
of which possess different treatment options and strategies. Due 
to the complex treatment of MRSA, as well as the concern over 
the development of resistance, suggested treatment guidelines are 
critical for improvement in clinical outcomes. The recently pub-
lished IDSA guidelines come in lieu of those previously published 
in 2006 by the UK The U.S. publication was most likely prompted 
due to an article published in The Journal of the American Medical 
Association (JAMA) suggesting MRSA was twice as common as 
other invasive infections and correlated with significant mortality. 
Although the publication of new evidence-based guidelines for the 
treatment of MRSA will most likely result in improved therapeutic 
outcomes, it is pertinent that health care providers receive adequate 
education regardlng the use of the guidelines. 
Background 
Antibacterial resistance is problematic and continues to increase despite 
efforts to halt its expansion. Antibacterials have been used to treat 
infectious diseases over the last 70 years. The long-term and improper 
use of antibacterials has caused bacteria to develop resistance to 
specific drugs and sometimes entire drug classes. 1 Staphylococcus 
aureus (S. aureus) is a gram-positive coccus that is part of the normal 
skin flora and is prevalent in the environment. Staphylococcus infections 
normally occur due to compromised host defenses and can cause a 
variety of clinical syndromes with varying severity and symptomatology 
in both community and hospital settings.1 Normally, S. aureus would be 
susceptible to the beta-lactam class of antibiotics with methicillin as the 
original treatment of choice for Staphylococcus infections. The beta-
lactam antibiotics exert their antibacterial action by binding to penicillin-
binding proteins (PBPs) located in bacterial cell walls, inhibiting cell wall 
biosynthesis and ultimately causing cell lysis and death.2 However, S. 
aureus has grown resistant to methicillin treatment by a mechanism 
decreasing binding of beta-lactams to PBPs. Methicillin-resistant Staphy-
lococcus aureus (MRSA) produces a different PBP known as PBP2a, 
binding beta-lactam antibiotics with much less affinity than PBP. PBP2a 
is encoded by mecA gene, which is contained in the Staphylococcal 
cassette chromosome (SCC). Currently, at least five types of sec are 
known (1-V), and mecA IV has four subtypes (a-d), which are all used to 
classify MRSA strains.3 
Community-acquired MRSA (CA-MRSA) is normally type IV or V, and 
more virulent than hospital-acquired MRSA (HA-MRSA}. CA-MRSA 
most commonly presents as a skin infection and is usually spread 
through contact with another person's skin infection or personal items 
that have been contaminated, such as towels, razors or bandages. This 
transmission usually occurs through close skin-to-skin contact or open 
skin wounds, such as abrasions or cuts. With these conditions, locations 
where people are in close contact (athletic facilities, dormitories, daycare 
centers and correctional facilities) are at higher risk for infection spread. 
CA-MRSA is susceptible to a variety of non-beta-lactam antibiotics and 
has more treatment options. 
In contrast, HA-MRSA is typically more resistant because the sec types 
I, II, and Ill in the strains common to this setting can carry resistance 
genes. In the health care setting, MRSA is most commonly transmitted 
through unclean hands of personnel or improper use of equipment and 
devices. Appropriate hand-washing with hot soap and water or using an 
alcohol-based hand sanitizer, as well as appropriate isolation proce-
dures with infected individuals, can help prevent the spread of MRSA. 
Due to the prevalence of multidrug resistance of types I, II, and Ill com-
mon to HA-MRSA, this type has fewer treatment options. 
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CA-MRSA Treatment Options 
CA-MRSA most commonly presents as skin and soft tissue infections (SS-
Tis) clinically ranging from impetigo to life-threatening necrotizing fasciitis.4 
This is associated with a cytotoxin, Panton-Valentine leukocidin (PVL), 
which causes cell lysis of the human leukocytes. PVL is also related to 
nectrotizing pneumonia and sepsis, although these severe conditions oc-
cur infrequently.3 The primary treatment of abscesses is surgical drainage, 
but antibiotic therapy is recommended with certain conditions. The treat-
ment duration is five-10 days but should be individualized based on the 
patient's clinical response.5 Oral drug therapy options include the following: 
sulfamethoxazole/trimethoprim (SMX!TMP) one to two double-strength 
tablets twice daily to three times daily, clindamycin 300-450 mg three times 
daily, doxycycline 100 mg twice daily, linezolid 600 mg every 12 hours.5•6 
Potential clindamycin resistance exists, and a double-disc diffusion assay 
"D-tesf' should be performed to determine macrolide-lincosamide-strepto-
gramin type B (MLS8) inducible resistance.5 
HA-MRSA Treatment Options 
Although CA-MRSA also would be susceptible to these antibacterials, 
these are not the recommended treatment options as a result of cost 
and resistance concerns. On the contrary, the therapies for HA-MRSA 
should never be used in CA-MRSA treatment strategies due to high 
prevalence of resistance. 
Daptomycin (Cubicin®) 
Daptomycin is a lipopeptide class antibiotic that has FDA labeled and 
unlabeled indications in the management of MRSA. The normal adult 
dose is 4-6 mg/kg once daily for one to six weeks.6 This medication 
should not be used in MRSA presentations of pneumonia, as it is inac-
tivated by lung surfactant.5 Cases of eosinophilic pneumonia have been 
reported, and it is recommended to discontinue daptomycin use if this 
condition is suspected.6 
Linezolid (Zyvox®) 
Linezolid is an oxazolidinone class antibiotic that has 100 percent oral 
bioavailability and, therefore, should be used orally unless contraindicated. 
Long-term use is limited by hematologic toxicity, so CBC should be checked 
weekly.5 The normal dose is 600 mg every 12 hours for two to eight weeks.6 
Rifampin 
Because of resistance, rifampin is not used as monotherapy to treat 
MRSA. It has been used as synergy in some situations, although its 
definitive role as adjunctive therapy has not been established.5 
Telavancin (Vibativ®) 
This lipoglycopeptide is active against MRSA as well as vancomycin-
intermediate S. aureus (VISA) and vancomycin resistant S. aureus 
(VRSA).5 It is approved for SSTls with a normal adult dose of 10 mg/kg 
IV every 24 hours for one to two weeks.6 Renal adjustments are needed, 
and nephrotoxicity is a concern with its use.5 
Tigecycline (Tygacit®) 
A derivative of tetracyclines, tigecycline has activity against gram-
positive and gram-negative organisms, including MRSA. It can only be 
administered intravenously, with an initial dose of 100 mg followed by a 
maintenance dose of 50 mg every 12 hours for seven to 14 days. The 
most common side effects are nausea, vomiting and diarrhea. An advan-
tage to using this medication is that it is not renally adjusted.6 
Vancomycin (Vancocin®) 
Vancomycin is a glycopeptide antibiotic that has been the drug of choice 
for MRSA and has been used since the 1950s. Efficacy is related to the 
area under the curve (AUC) and the minimal inhibitory concentration (MIC). 
Patient weight, renal function and the severity of the disease affect dosing 
requirements.7 Some experts use combination therapy with rifampin and 
gentamicin for synergy, especially for more serious infections such as pros-
thetic valve endocarditis. Normal adult dosing is usually between 15-20 mg/ 
kg/dose every eight to 12 hours, with treatment duration depending on the 
clinical syndrome. Initial doses are based on actual body weight, and serum 
trough levels should help determine the subsequent doses. Rapid intrave-
nous administration may cause a reaction known as "Red Man's Syndrome," 
which is characterized by hypotension and a rash of the upper body.6 
Guidelines 
In 2004, Wessex microbiologists reviewed the management of MRSA and 
survival rates of patients with a MRSA infection in participating British hospi-
tals.8 Between March 1995 and December 2003, only 64 percent of patients 
with MRSA lived longer than 28 days, which was considered unacceptable 
and spurred the National Institute for Health and Clinical Excellence (NICE) 
to create guidelines on the management of MRSA. 8 In 2006, a joint Working 
Party of the British Society for Antimicrobial Chemotherapy published new 
guidelines that focused on the prophylaxis and treatment of MRSA infections 
in the U.K.9 The first U.S. guidelines were published five years after those 
in the U.K., but the Infectious Diseases Society of America (IDSA) did not 
provide a direct explanation for their need. It is possible the guidelines pub-
lished by the IDSA were prompted by an article published by The Journal of 
the American Medical Association (JAMA) in October 2007, which assessed 
the incidence of invasive MRSA in 2005. The standardized incidence rate 
was revealed to be 31.8 per 100,000 persons.1° Compared to other invasive 
infections such as S. pneumoniae or H. influenzae, MRSA was twice as 
common and associated with increased mortality.10 Ideally, the implemen-
tation of the recently published U.S. guidelines will result in reduced drug 
resistance and improved patient outcomes. 
Table 1. U.K. Practice Guidelines Strength of Evidence Categories9•11 
Category Definition 
IA Strongly recommended for implementation and strongly 
supported by well-designed experimental, clinical or 
epidemiological studies 
IB Strongly recommended for implementation and sup-
ported by certain experimental, clinical or epidemiologi-
cal studies and a strong theoretical rationale 
IC Required for implementation as mandated by federal or 
state regulation or standard or representing an estab-
lished association standard 
II Suggested for implementation and supported by 
suggestive (non-definitive) clinical or epidemiological 
studies or a theoretical rationale 
Unresolved No recommendation is offered. No consensus reached, 
issue or insufficient evidence exists regarding efficacy. 
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New evidence emerged shortly after the release of the first guidelines 
(2006), which fueled new recommendations, and an update was 
published in March 2009.11 The initial guidelines did not provide any 
recommendations for treatment of impetigo and boils, but the update 
included a category II recommendation to treat impetigo due to MRSA 
with topical mupirocin or fusidic acid, if susceptible, and to not use anti-
biotics for small boils. The updated version also differentiates between 
treatment for hospitalized and non-hospitalized patients with cellulitis 
or surgical site infections, including step-therapy based on antibiotic 
susceptibility. The recommendation to use rifampin in addition to fusidic 
acid to treat SSTls was removed due to adverse effects and newer, 
less-toxic options such as daptomycin and tigecycline. Clindamycin was 
designated as the antibiotic of choice, and the new guidelines empha-
size the importance of patient education on diarrhea due to clindamy-
cin-associated C. difficile. First-line treatment options for uncomplicated 
urinary tract infections (UTls) due to MRSA now include oral nitrofuran-
toin, trimethoprim, SMX/TMP in addition to tetracycline based on in vitro 
susceptibility. Complicated UTls should be treated with a glycopeptide 
or daptomycin. When treating bacteremia and endocarditis, the previ-
ous category IA recommendation of 14-day minimum treatment with a 
glycopeptide or linezolid for uncomplicated cases and longer treatment 
periods for high-risk patients remains, although it is now a category II 
recommendation with daptomycin also recognized as an alternative 
treatment option. The initial guidelines provided a category II suggestion 
to use non-glycopeptide agents to treat bronchiectasis without pneumo-
nia, but upon review of current evidence, this is considered an unre-
solved issue, with linezolid as a preferred treatment option due to better 
penetration into lung tissue (category IC). The recommendation remains 
to use glycopeptides or linezolid for lower respiratory tract infections 
due to MRSA. Fucidic acid has been added as an appropriate option to 
treat susceptible superficial eye infections. 
Table 2. IDSA Practice Guidelines Strength of Evidence Categories5 
Category/grade Definition 
A Good evidence to support a recommendation for 
or against use 
B Moderate evidence to support a recommenda-
tion for or against use 
c Poor evidence to support a recommendation 
I Evidence from ::::1 properly randomized, con-
trolled trial 
II Evidence from ::::1 well-designed clinical trial 
without randomization; from cohort or case-
controlled analytic studies (preferably from 
> 1 center); from multiple time series; or from 
dramatic results from uncontrolled experiments 
Ill Evidence from opinions of respected authorities, 
based on clinical experience, descriptive stud-
ies, or reports of expert committees 
As of February 2011, the Infectious Diseases Society of America (IDSA) 
has published the first evidence-based medicine (EBM) U.S. guidelines 
for the treatment of MRSA. The guideline was formulated by an expert 
panel in the area of infectious disease as it pertains to MRSA.5 The 
objective of this new guideline is to provide recommendations on the 
management of some of the most common clinical syndromes encoun-
tered by adult and pediatric clinicians who care for patients with MRSA 
infections.5The guideline also addresses several issues pertaining to 
treatment of MRSA with vancomycin, such as dosing, monitoring and 
problems regarding susceptibility testing. This guideline specifically 
states it does not address the issues of surveillance or MRSA-prevention 
strategies. Several clinical questions pertaining to different clinical syn-
dromes, such as SSTls, bacteremia, endocarditis, pneumonia, bone and 
joint infections and CNS infections associated with MRSA, are answered 
within this guideline. Table 3 summarizes the three sets of guidelines 
and each of the recommendations made for each clinical syndrome. The 
recommendations listed are those that received the highest evidence 
grade for each respective syndrome. 
Evidence Based Medicine (EBM) 
EBM is grounded in the idea of creating a method to effectively rank evi-
dence according to its statistical strength and the accuracy of results. 12 
In most cases, EBM relies on a grading system to assess the character-
istics of the methods utilized to conduct the evidence-gathering process 
and subsequent analysis of this gathered evidence. EBM takes into 
consideration study type, randomization, blinding, selection of subjects 
and controls, and all of the procedures associated with these events. 
With the ranking system EBM utilizes, evidence can be adequately as-
sessed for strength and quality and, therefore, can be applied appropri-
ately to therapeutic decision-making. Without the use of EBM, evidence 
with inadequate or potentially inaccurate conclusions has the potential 
to be applied and, hence, result in the generation of poor or suboptimal 
therapeutic outcomes. Within the 2011 IDSA guidelines, evidence was 
graded according to the quality of evidence (Table 2). These grades 
were then used to generate strength of recommendation. Strengths were 
A, B and C conveying good, moderate and poor evidence to support a 
recommendation, respectively. It is pertinent to note the IDSA guidelines 
follow evidence-based medicine practices when it comes to evaluating 
the evidence and, therefore, have the potential to influence health out-
comes positively. Within the clinical guideline summary, only the highest 
recommendations were listed, as there are many different treatment 
options available. 
Importance of and Adherence to Guidelines 
The new U.K. guidelines did not prove to decrease mortality rates, ac-
cording to a retrospective study completed in January 2009, three years 
after the initial guidelines were published.8 Data for 1,679 patients from 
seven hospitals was divided into three groups based on the collec-
tion date of a positive MRSA blood culture. Group A included patients 
through 2003 (when it was decided to create the guidelines), group 
8 included patients from 2004 and 2005 (during the formation of the 
guidelines), and group C included patients from 2006 to 2008 (after 
publication of the guidelines). Physicians were 96 percent compliant 
with the guidelines. Survival rates of the different groups did not differ, 
but the number of MRSA bacteremias decreased from 300 in 2004 to 
111 in 2008. This suggests that, although the guidelines did not improve 
survival rates, they were effective in decreasing the number of infections 
per year. The study also showed an inverse relationship between sur-
vival rates and age of the patient, implying survival rates may be more 
dependent on patients' co-morbidities than MRSA. 
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Table 3. Summary and Comparison of U.K. and U.S. Guidelines 5•9•11 
2006 U.K. guidelines 
SS Tis 
Impetigo and No recommendation 
Boils 
Ulcers and Bolls 
Cellulitls/Surgical Tetracyclines* 
Site Infections 
Glycopeptides or Linezolid** 
IV infusion sites Severe: glycopeptides or 
linezolid 
Mild: other oral agents 
Urinary Tract Tetracyclines or alternatively 
Infections trimethoprim or nitrofurantoin 
Bone and Prosthetic joint Vancomycin + rifampin or 
Joint lnfec- infection vancomycin + fusidic acid 
tions 
Other Rifampin + a fluoroquinolone 
or trimethoprim or fusidic 
acid 
Bacteremia Uncomplicated 14 day minimum linezolid or 
and endocar- bacteremia glycopeptides 
ditis 
(linezolid limitation here) 
Complicated Longer treatment 
bacteremia or 
endocarditis 
Respiratory Upper Respiratory See cellulitis recommenda-
tract infec- Tract Infection tions 
tions 
Lower Respiratory Glycopeptides or linezolid 
Tract Infection 
Eye and CNS Insufficient evidence for 
infections deep eye and CNS infec-
tions. Superficial infections: 
gentamicin or chlorampheni-
col 
Elimination Mupirocin in combination 
of carriage with a systemic agent 




*Unless there 1s a nsk of bacterem1a or endocard1t1s 
**If the risk of bacteremia is high 
2008 U.K. guideline update 
Topical mupirocin or fusidic acid 
(unless small and not surrounded 
by cellulitis) 
Doxycycline or clindamycin** 
No change 
Simple: oral trimethoprim, 
nitrofurantoin, or SMX/TMP or 
tetracycline 






Linezolid offers good penetration 
No change 
Superficial infections: gentamicin 
or chloramphenicol or fusidic acid 
No change 
No change 
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2011 U.S. ISDA guidelines +strength 
of evidence 
Simple abcesses/boils: incision and 
drainage (All) 
Purulent cellulitis: Clindamycin, SMX/ 
TMP, doxycycline, minocycline, linezolid 
(All) 
Non-purulent cellulltis: '3-lactam, 
clindamycin, linezolid (All) 
Complicated: Vancomycin, linezolid 
(Al/II) 
n/a 
Osteomyelitis: Vancomycin (Bii/Aii) 
Septic arthritis: Vancomycin (Bil/All) 
Bacteremia/endocardltls/infective 
endocarditls with native valve: vanco-
mycin (Biii) 
Infective endocardltis with prosthetic 
valve: vancomycin + gentamicin + 
rifampin (Biii) 
n/a 
Vancomycin, linezolid (All) 
Vancomycin or linezolid {Bii) 
n/a 
n/a 
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A questionnaire assessing health care workers' awareness of the MRSA 
practice guidelines revealed an inadequate knowledge of current MRSA 
practice guidelines in 2009, three years after they were released. 13 The 
questionnaire contained 10 true-or-false questions, and the scores of 
physicians (6.532) and trainee surgeons (6.904) were compared to 
control groups of infectious control nurse practitioners (8.391) and non-
clinical scientific staff (4.7). The results demonstrated room for signifi-
cant improvement among physicians and trainee surgeons, although the 
study had a few major limitations. The study did not randomly sample 
the studied populations (physicians and surgeons surveyed attended a 
medical conference), and there was no evaluation of random answers. 
This study suggests health care workers must be thoroughly educated 
for guidelines to be maximally effective. 
Conclusion 
Development of EBM guidelines has the potential to significantly impact 
both CA-MRSA and HA-MRSA treatment strategies via the standardiza-
tion of therapy based on graded clinical data. Education of health care 
providers on the usage of the guidelines has the potential to change 
the clinical outcomes of treatment of MRSA infection. With appropriate 
education, inappropriate medication usage has the potential to de-
crease development of resistance, patient length of stay in the hospital, 
and use of unnecessary treatment for the presenting syndrome. All of 
these factors lead not only to improved patient quality of life, but also 
to decreased health care costs. Overall, use of the guidelines has the 
potential to impact a variety of clinical and economic factors supporting 
its usage in the treatment of MRSA infection. 
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Assessment Questions 
1. S. aureus has become resistant to beta-lactams, such as methicillin, 
due to: 
a. Decreased binding to penicillin-binding proteins 
b. Production of beta-lactamases 
c. Increased activity of efflux pumps 
d. Altered metabolic pathways 
2. What type of SCC characterizes CA-MRSA? 
a. I or II 
b.11 or Ill 
c.111 or IV 
d. IV orV 
3. All of the following are locations with a high-risk of CA-MRSA 
transmission EXCEPT: 
a. Correctional facilities 
b. Daycare centers 
c. Grocery stores 
d. Athletic locker rooms 
4. Which of the following is an option to treat CA-MRSA? 
a. Vancomycin 1 g IV BID 
b. Doxycycline 100 mg po BID 
c. Oxacillin 2 g IV 06 hr 
d. Linezolid 600 mg po BID 






6. The 2009 updated U.K. guidelines did not include the recommenda-
tion to use rifampin + fusidic acid to treat SSTls due to: 
a. Adverse effects 
b. Improved newer drug options 
c. Increased resistance 
d. A and B 
7. The recently published ISDA guidelines for the U.S. suggests treating 
simple abcesses/boils with: 
a. Incision and drainage only 
b. Incision and drainage with topical mupirocin 
c. Vancomycin 
d. Doxycycline 





9. The strongest level of evidence is associated with well-designed: 
a. Professional opinions 
b. Multiple meta-analysis 
c. Randomized controlled trials 
d. Cohort studies 
10. In order for the ISDA guidelines to be effective: 
a. The guidelines should help determine treatment strategies 
b. Health care workers must be knowledgeable 
c. Health care works should be educated about MRSA transmission 
d. All of the above 
Ohio Northern University is accredited by the Accreditation 
Council for Pharmacy Education as a provider of continuing 
pharmacy education. This program is eligible for credit until 
, April 5, 2014. 
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